Abstract
Epidermal growth factor receptor (EGF-R) expression was assessed in 63 lung tumour samples with a monoclonal antibody (EGF-R1) by indirect immunoperoxidase staining on cryostat sections. All 15 small cell lung cancer samples were negative whereas over 80% of the 48 non small lung cancer stained positively. In 30 bronchial biopsies two monoclonal antibodies against the cytoplasmic part of the EGF-R were evaluated. These antibodies showed weaker staining than EGF-R1. No additional or enhanced staining as compared with EGF-R1 was observed, suggesting a lack of enhanced expression of a truncated EGF-R analogous to the v-erb-B oncogene product. Monoclonal antibodies against the EGF-R may be helpful diagnostically in differentiating small cell from non small cell lung cancer and may also be important in elucidating biological differences in primary lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Cerny, T., Barnes, D., Hasleton, P. et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer 54, 265–269 (1986). https://doi.org/10.1038/bjc.1986.172
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.172
- Springer Nature Limited
This article is cited by
-
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
Molecular Medicine (2021)
-
Network Understanding of Herb Medicine via Rapid Identification of Ingredient-Target Interactions
Scientific Reports (2014)
-
The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation
Oncogene (2013)
-
Formation of translational risk score based on correlation coefficients as an alternative to Cox regression models for predicting outcome in patients with NSCLC
Theoretical Biology and Medical Modelling (2011)
-
EGFR mutations and the terminal respiratory unit
Cancer and Metastasis Reviews (2010)